The MRI Only Prostate External Radiotherapy (MR-OPERA) study is now published in the November issue of the prestigious International Journal of Radiation Oncology (a.k.a. the Red Journal). The MR-OPERA study comprises a joint effort by four Swedish university hospitals, involving 170 patients, aiming at validating the use of Spectronic Medical's MriPlanner technology for prostate cancer radiotherapy.

"The MR-OPERA study is the world's largest study evaluating an MRI only workflow for radiotherapy planning. The fantastic efforts made by the participating hospitals to make this study possible shows how important our technology is to the future of radiotherapy", says Carl Siversson, CEO of Spectronic Medical.

The uniform conclusion of the study is that MRI only radiotherapy planning using MriPlanner is both accurate and robust, and also works well with a large variety of MRI scanners and clinical environments.

"The extraordinary results shows not only that our technology works very well, but also that it is now ready for large-scale deployment", says Carl Siversson and continues, "The advantages of an MRI only workflow are enormous. Not only are costs reduced and patient comfort increased, but it also opens up for personalized treatment strategies with significant therapeutic benefits"

MriPlanner is currently CE marked and ready for prostate radiotherapy planning in Europe and other regions acknowledging the CE mark. FDA approval for the US market will follow soon.

The complete MR-OPERA study can be read here:

http://www.redjournal.org/article/S0360-3016(17)31055-6/pdf

A major milestone is now reached in Spectronic Medical's development history. During the past weeks, the first set of prostate cancer patients were successfully treated at Skåne University Hospital using Spectronic Medical's MriPlanner technology. In total 60 patients are included for therapy at Skåne University Hospital using MriPlanner during 2016.

"This is not only a milestone for us but also for the national medical achievements in this field, as these treatments are the first of their kind ever to be performed in Sweden. Our MRI only radiotherapy planning technology not only reduces treatment complexity but also opens up for very exciting personalized and adaptive treatment planning strategies." says Carl Siversson, CEO of Spectronic Medical.

The MR Only Prostate External Radiotherapy (MR-OPERA) multi center validation study is presented at the ESTRO scientific conference in Vienna May 5-9. The national MR-OPERA study was performed as a collaboration between Skåne University Hospital, Norrland University hospital, Sahlgrenska University Hospital and Karolinska University hospital aiming to verify and validate Spectronic Medical's MriPlanner technology with a large cohort of 170 prostate cancer patients.

"The results presented at ESTRO are very exciting and confidently shows that our technology is robust and ready for large-scale clinical implementation", says Carl Siversson, CEO of Spectronic Medical.

The study will be presented by first author Emilia Persson from Lund University on Saturday May 6. Spectronic CEO Carl Siversson will also attend ESTRO. Please contact us if you wish to arrange a meeting at ESTRO.

At an event hosted by NyTeknik and Affärsvärlden at Münchenbryggeriet in Stockholm, Spectronic Medical was awarded as one of Sweden's 33 hottest young technology companies.

"We are very happy for this recognition", says Carl Siversson, CEO of Spectronic Medical, "This award verifies our understanding that the market is now asking for the type of advanced AI driven med-tech technology we are providing".

Apart from receiving the award, Spectronic Medical also participated the event with a booth displaying its technology to a wider audience.

The awards were further recognized by Nasdaq at Times Square in New York.




Read more here:

http://www.nyteknik.se/startup/33-listan/33-nya-vinnare-tar-plats-pa-historiska-listan-6838439
https://sv-se.facebook.com/33listan

In tough competition Spectronic Medical came out on top in the 33-list* pitching competition held in Malmö on the 8th of March. Thereby Spectronic Medical has now earned a place one 33-list; enlisting the 33 hottest young technology companies in Sweden.

The Jury Motivation:
"Spectronic Medical uses powerful, self-learning algorithms with ingenious elimination of CT radiation to create a cancer treatment that is more precise, gentle, and without human error."

Read more on the links below (in Swedish):

Ny Teknik: http://www.nyteknik.se/startup/33-listan/spectronic-medical-vann-33-plats-i-malmo-6830981

Winning interview with Spectronic Medical's CEO Carl Siversson: https://www.facebook.com/nyteknik/videos/790705387746955/?hc_ref=PAGES_TIMELINE

Affärsvärlden: http://www.affarsvarlden.se/bors-ekonominyheter/spectronic-medical-vann-33-plats-i-malmo-6831016


*The 33-list, listing "Sweden's 33 hottest young technology companies", is compiled jointly by the editorial staff of the magazines Ny Teknik and Affärsvärlden. The complete list of all companies will be presented in Stockholm on the 4th of April at Münchenbryggeriet.

Spectronic Medical is selected to join the 33-list pitching competition for a place on the 33-list. The 33-list, listing "Sweden's 33 hottest young technology companies", is compiled jointly by the editorial staff of the magazines Ny Teknik and Affärsvärlden. “It is very exciting to be selected to present our technology to a wider audience” said Dr. Carl Siversson, CEO of Spectronic Medical. “While there only is a very short time for presenting a complex technology we will gladly take on the challenge to spread awareness of the positive development going on within the cancer care area”.

Wish us good luck and join us, for free, at Media Evolution in Malmö on the 8th March. Sign up at: http://talentumevents.se/33listan/

The gentle radiotherapy research project aims to create a large-scale national cancer therapy platform, with fully integrated MRI only workflow in the participating clinics. The individual clinics are responsible for developing treatment procedures for a specific cancer diagnosis; e.g. prostate, rectum, head-neck and brain. Hence, the project as a whole aims to cover the major parts of the body where MR images are relevant for therapy. The role of Spectronic Medical in the project is to supply the technology for creation of synthetic CT’s (sCT) as well as technology for QA of geometric distortion.

“The steps taken by Gentle Radiotherapy project to advance MRI only treatment planning are very well aligned with our development efforts” says Dr. Carl Siversson, CEO of Spectronic Medical. “We are of course supporting the transition to MRI only based treatments and will strengthen our development efforts to be able to supply technology for more anatomical regions”.

Today Spectronic Medical have a CE Marked product for generation of sCT’s for prostate cancer radiotherapy.